Abhishek Maan1, Neal W Jorgensen2, Moussa Mansour3, Samuel Dudley1, Nancy S Jenny4, Christopher Defilippi5, Moyses Szklo6, Alvaro Alonso7, Marwan M Refaat8, Jeremy Ruskin3, Susan R Heckbert9, E Kevin Heist3. 1. Division of Cardiology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island. 2. Department of Biostatistics, University of Washington, Seattle, Washington. 3. Cardiac Arrhythmia Service and Heart Center, Massachusetts General Hospital, Boston, Massachusetts. 4. Laboratory for Clinical Biochemistry Research, University of Vermont College of Medicine, Burlington, Vermont. 5. Division of Cardiovascular Medicine, University of Maryland, Baltimore, Maryland. 6. Departments of Epidemiology and Medicine, The Johns Hopkins University, Baltimore, Maryland. 7. Division of Epidemiology and Public Health, University of Minnesota, Minneapolis, Minnesota. 8. Department of Internal Medicine, Cardiology/Cardiac Electrophysiology and Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon. 9. Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington.
Abstract
BACKGROUND: During atrial fibrillation (AF), a high rate of myocyte activation causes cellular stress and initiates the process of atrial remodeling, which further promotes persistence of AF. Although heat shock proteins (HSPs) have been shown to prevent atrial remodeling and suppress the occurrence of AF in cellular and animal experimental models, increased levels of HSP-60 have been observed in patients with postoperative AF, likely reflecting a response to cellular stress. To better understand the role of HSP-60 in relation to AF, we examined the association of HSP-60 levels in relation to the future development of AF in the Multi-Ethnic Study of Atherosclerosis (MESA). METHODS: MESA is a cohort study that recruited 6,814 participants aged 45-84 years and free of known cardiovascular disease at baseline (2000-2002) from six field centers. We investigated 983 participants, selected at random from the total cohort, who had HSP-60 measured and were free of AF at baseline. We tested the association of HSP-60 levels with the incidence of AF using multivariate Cox models after adjustment for demographics, clinical characteristics, and biomarkers. RESULTS: During an average of 10.6 years of follow-up, 77 participants developed AF. We did not observe a significant association between the log-transformed HSP-60 levels and development of AF on either unadjusted or multivariate analysis (adjusted hazard ratio: 1.02 per unit difference on natural log scale, 95% confidence interval: 0.77-1.34 ln (ng/mL). CONCLUSION: Contrary to the findings from the preclinical studies, which demonstrated an important role of HSP-60 in the pathogenesis of AF, we did not observe a significant association between HSP-60 and occurrence of AF.
BACKGROUND: During atrial fibrillation (AF), a high rate of myocyte activation causes cellular stress and initiates the process of atrial remodeling, which further promotes persistence of AF. Although heat shock proteins (HSPs) have been shown to prevent atrial remodeling and suppress the occurrence of AF in cellular and animal experimental models, increased levels of HSP-60 have been observed in patients with postoperative AF, likely reflecting a response to cellular stress. To better understand the role of HSP-60 in relation to AF, we examined the association of HSP-60 levels in relation to the future development of AF in the Multi-Ethnic Study of Atherosclerosis (MESA). METHODS: MESA is a cohort study that recruited 6,814 participants aged 45-84 years and free of known cardiovascular disease at baseline (2000-2002) from six field centers. We investigated 983 participants, selected at random from the total cohort, who had HSP-60 measured and were free of AF at baseline. We tested the association of HSP-60 levels with the incidence of AF using multivariate Cox models after adjustment for demographics, clinical characteristics, and biomarkers. RESULTS: During an average of 10.6 years of follow-up, 77 participants developed AF. We did not observe a significant association between the log-transformed HSP-60 levels and development of AF on either unadjusted or multivariate analysis (adjusted hazard ratio: 1.02 per unit difference on natural log scale, 95% confidence interval: 0.77-1.34 ln (ng/mL). CONCLUSION: Contrary to the findings from the preclinical studies, which demonstrated an important role of HSP-60 in the pathogenesis of AF, we did not observe a significant association between HSP-60 and occurrence of AF.
Authors: Bianca J J M Brundel; Robert H Henning; Lei Ke; Isabelle C van Gelder; Harry J G M Crijns; Harm H Kampinga Journal: J Mol Cell Cardiol Date: 2006-07-31 Impact factor: 5.000
Authors: Abdulla A Damluji; Archana Ramireddy; Mohammed S Al-Damluji; George R Marzouka; Lynda Otalvaro; Juan F Viles-Gonzalez; Chunming Dong; Carlos E Alfonso; Robert C Hendel; Mauricio G Cohen; Mauro Moscucci; Nanette H Bishopric; Robert J Myerburg Journal: Heart Date: 2015-01-05 Impact factor: 5.994
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Bianca J J M Brundel; Lei Ke; Anne-Jan Dijkhuis; XiaoYan Qi; Akiko Shiroshita-Takeshita; Stanley Nattel; Robert H Henning; Harm H Kampinga Journal: Cardiovasc Res Date: 2008-03-07 Impact factor: 10.787
Authors: Renate B Schnabel; Xiaoyan Yin; Philimon Gona; Martin G Larson; Alexa S Beiser; David D McManus; Christopher Newton-Cheh; Steven A Lubitz; Jared W Magnani; Patrick T Ellinor; Sudha Seshadri; Philip A Wolf; Ramachandran S Vasan; Emelia J Benjamin; Daniel Levy Journal: Lancet Date: 2015-05-07 Impact factor: 79.321
Authors: John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal Journal: Expert Rev Cardiovasc Ther Date: 2018-12-29
Authors: Tsz Him Hui; Robyn L McClelland; Matthew A Allison; Carlos J Rodriguez; Richard A Kronmal; Susan R Heckbert; Erin D Michos; Philip J Barter; Kerry-Anne Rye; Kwok Leung Ong Journal: Atherosclerosis Date: 2017-12-25 Impact factor: 5.162
Authors: Denise M S van Marion; Eva A H Lanters; Kennedy S Ramos; Jin Li; Marit Wiersma; Luciënne Baks-Te Bulte; Agnes J Q M Muskens; Eric Boersma; Natasja M S de Groot; Bianca J J M Brundel Journal: Cells Date: 2020-09-16 Impact factor: 6.600